CS Paper Radar

How Robust Are Prognostic Radiomic Features? Comparing Selection Techniques on Pooled Glioblastoma Cohorts

Yannick Sodonougbo, Marlene Schnieders, Alexia Rizoudis, Santiago Cepeda, Frank Kramer, Dominik Müller

cs.CV cs.AIq-bio.QM ·submitted 2026-10-19 09:56 UTC · v1

Abstract

Radiomic survival studies in glioblastoma report heterogeneous prognostic features, but how much of this stems from the methodology itself is rarely examined. We analysed the association of 463 radiomic, anatomical and clinical features from pre-treatment MRI with overall survival in 705 IDH-wildtype glioblastoma patients from three public cohorts, using three techniques: a log-rank test after median split, univariate Cox regression (both Benjamini-Hochberg corrected) and an XGBoost regressor interpreted with SHAP. The log-rank test selected 99 features, Cox regression 72 and SHAP its top 20; five were selected by all three: age, a peritumoural T2 texture feature, the number of connected peritumoural mask components and two image-level intensity maxima. The two survival tests shared 51 features, about half of the SHAP top 20 were also selected by either test, and where selections overlapped, effect directions agreed. Many selections were PyRadiomics diagnostic descriptors that are not restricted to tumour voxels. Analytical pipeline choices, including ranking method, pre-filtering and descriptor handling, can substantially influence which features appear prognostic.

Comment
7 pages, 1 figure

Closest papers

Nearest neighbours by meaning across the whole index.

A four-step validation protocol for radiomic survival analysis in small cohorts: a body composition case study

eess.IV cs.CVcs.LG ·2026-11-09 ·Mariela Talavera-Muñoz, Cecilia Diana-Albelda, Miguel Antonio Sampedro-Nuñez, Victor Rodriguez-Laval, Jesus Bescos +1 more
code/data similarity 0.67
Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NET) lack prognostic biomarkers, and computed tomography (CT)-based body composition radiomics at the third lumbar vertebra (L3) is a promising candidate. Small cohorts make high-dimensional radiomic models prone to overfitting and single-split evaluations variable and optimistic. This methodological study proposes a four-step validation protocol for radiomic survival analysis in small cohorts: (1) false discovery rate (FDR)-corrected feature selection, (2) a dual-path comparison of prior feature selection versus embedded regularization, (3) repeated nested cross-validation (CV) and (4) a negative control with Gaussian noise features. In 78 GEP-NET patients, 535 radiomic features from five L3 compartments were used to evaluate five survival models with Harrell's concordance index (C-index), time-dependent area under the curve (AUC) and integrated Brier score (IBS). Step 1 selected at least one feature in 18% of outer folds under noise (nominal level 20%) versus 84% with radiomic features. The dual-path comparison showed no consistent difference between strategies. Repeated nested CV reduced variability across seeds (41% median reduction in C-index standard deviation), but not enough to distinguish models. The nested CV C-index exceeded chance by 0.07-0.15 with radiomic features but not clearly under noise (0.40-0.42 with prior feature selection, 0.47-0.55 with embedded regularization). Frequently selected features tentatively linked greater subcutaneous fat, skeletal muscle compactness and texture to better prognosis. These findings suggest a modest prognostic signal in L3 radiomics, with considerable uncertainty that the protocol quantifies. The protocol may transfer to other small-cohort radiomic survival studies. Code: https://github.com/marielatalaveram/radiomics-survival-validation-protocol.

0.30

Resampling-based batch reweighting for ComBat harmonization of MRI radiomic features in a multi-scanner glioma cohort

eess.IV physics.med-ph ·2026-11-01 ·Rifa Sajda Tasnim, Yushuf Sharker, Md Forhad Hossain, Rakibur Rahman, Enamul Hoque Bhuiyan
published similarity 0.66
Abstract · Original article. Submitted to Journal of Magnetic Resonance Imaging (JMRI)

Radiomic features derived from magnetic resonance imaging (MRI) are sensitive to scanners; therefore, they require harmonization across scanners. In a radiomic feature dataset, some batches may be severely underrepresented compared to the others e.g., the Erasmus Glioma Database, which may provide harmonized features biased towards the larger batches in the dataset. We investigated whether reweighting underrepresented scanner batches before empirical-Bayes ComBat estimation improves feature harmonization and reduces residual scanner association while retaining grade-related information. In this retrospective, the Erasmus Glioma Database included 733 eligible patients acquired at a single center across nine vendor-by-field-strength configurations. Structural MRI acquired at 1 T, 1.5 T, and 3 T; four structural MRI sequences were analyzed. From four structural MRI sequences, 428 features were computed using an IBSI-compliant PyRadiomics implementation. The sample sizes of some scanner batches were very small compared to others, which may produce unequal precision and shrinkage of batch-effect estimates. We proposed a data augmentation approach to overcome the limitation of ComBat. We provided exploratory evidence, along with confirmatory Kruskal-Wallis tests with a Benjamini-Hochberg correction to assess the proposed method. Before harmonization, 392/428 features (91.6%) differed significantly across scanner batches (median eta-squared=0.463). Standard ComBat reduced this to 13/428 (3.0%), whereas batch-augmented ComBat reduced it to 8/428 (1.9%); the median residual effect size was <0.001 for both harmonized conditions. Batch augmentation appeared to be a useful strategy to improve the performance of ComBat for feature harmonization under severe batch-size imbalance.

0.32

A Vision-Language Foundation Model for Precise and Comprehensive Brain Tumor Diagnosis from Preoperative Multimodal Data

cs.CV cs.AI ·2026-09-15 ·Yinong Wang, Jianwen Chen, Zhou Chen, Shuwen Kuang, Haoning Jiang +26 more
code/data similarity 0.61
Abstract · 94 pages, 22 Figures, supplement files, Project page link: https://hku-healthai.github.io/brainvlm_project.github.io/

We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted two proof-of-concept studies to validate its clinical utility in AI-clinician workflows: 1) a blinded multireader study where 12 neuroradiologists across varying experience levels interpreted 248 retrospective cases with or without AI assistance, and 2) a real-world prospective study in which 1,009 patients were independently and blindly assessed by BrainVLM and radiologists before surgery. Additionally, we demonstrated BrainVLM's utility in preoperative molecular subgroup prediction for adult-type diffuse gliomas, using a multi-center cohort of 632 patients. In primary evaluation, BrainVLM achieved an area under the curve (macro-AUC) of 0.85 (95% CI: 0.84-0.86), and an F1 score of 0.82 (95% CI: 0.81-0.83), surpassing neuroradiologists (F1 = 0.80 (95% CI: 0.79-0.81)). In external validation across 11 centers, BrainVLM achieved an AUC = 0.80 (95% CI: 0.79-0.82) and F1 = 0.75 (95% CI: 0.73-0.78), compared with F1 = 0.71 (95% CI: 0.69-0.73) for neuroradiologists. In prospective real-world evaluation, BrainVLM maintained performance comparable to neuroradiologists. The BrainVLM project page is available at https://hku-healthai.github.io/brainvlm_project.github.io/.

0.35

A new MRI-based feature for quantifying the Diffuse Low-Grade Glioma brain infiltration and discriminating patterns of patients

eess.SP stat.AP ·2026-10-05 ·Jean-Marie Moureaux, Sophie Wantz-M{é}zi{è}res, Cyril Brzenczek, Marie Blonski, Luc Taillandier
published similarity 0.61
Abstract

Gliomas are the most common type of primary brain tumors. Diffuse low-grade gliomas (DLGGs) are slow-growing tumors that are often minimally symptomatic for a long period of time. They progress to a higher grade, resulting in the patient's death. Treatments include surgery, chemotherapy and radiation therapy to control tumor progression. Responses to treatments are highly variable among patients. Furthermore, the diffuse component of this tumor entity has been observed but is not yet well measured. Here, we propose a new variable to quantify glioma morphology, called ESVR (Extra Sphere Volume Ratio). We use then a machine learning approach to study the importance of different variables for discriminating patterns of patients: patient-specific variables, genetic alterations of tumor tissue, and some image-based variables like ESVR and the volume of the tumor, obtained by MRI analysis. Our machine learning approach shows that the patient's age and ESVR at diagnosis, as well as the pathology results seem to play an important role. Taking the highlighted variables into account could thus help to model the tumor behavior. In association with other classical biomarkers, our new ESVR feature could help the clinician to manage the treatment, as it carries significant information in terms of aggressivity of the DLGG.

0.48

Evidence-Bound Reasoning: Neuro-Semantic Verification of Biomedical AI in Glioblastoma Radiogenomics

cs.CL ·2026-10-06 ·Mariya Miteva, Maria Nisheva-Pavlova
benchmark similarity 0.59
Abstract · 15 pages, 4 figures, 4 tables. Preprint

Background: Biomedical AI can generate plausible explanations without reliably verifying whether each statement is supported by patient-specific evidence. We developed a neuro-semantic verification framework that converts radiomic measurements into addressable evidence records and machine-checkable claims. Methods: UPenn-GBM radiomics were aligned with de novo CaPTk extraction from standardized MRI and expert-validated segmentations in an independent multicenter cohort. The shared space comprised 1,728 features from T1, T1GD, T2, and FLAIR MRI across three tumor regions. Reference-defined semantic states were derived from 611 UPenn cases. We evaluated cross-cohort transportability, model-linked provenance, deterministic verification, controlled predictive degradation, and an LLM claim-extraction pilot; MGMT prediction served only as a transport stress test. Results: Median semantic-state agreement was 0.786 (weighted kappa 0.709), ranging from 0.918 for morphologic to 0.252 for intensity features. The external evidence ledger contained 1,655 model-linked records for 331 patients. The verifier achieved 100% exact-set accuracy in a 6,620-claim corruption benchmark. In a 24-case pilot, GPT-5.6 Sol reproduced 72/72 prespecified atomic claims, and the frozen verifier recovered 24/24 expected conditions. During controlled degradation, ROC AUC declined from 0.899 to 0.500 while verification accuracy remained 1.000. External MGMT discrimination was weak (ROC AUC 0.543). Conclusions: Verifiability can be engineered and evaluated independently of predictive performance. LLMs may structure explanations, while final evidence-consistency checking remains deterministic.

0.23

The Diagnosis a Reporter Leaves Unspoken: Surfacing Frozen Tumor Features for Brain-Tumor MRI Reporting

cs.CV ·2026-09-02 ·Khawaja Murad ul Hassan, Ruqiyya Adil, Adil Qayyum, Rida Hassan, Asad Mansoor Khan +2 more
published similarity 0.59
Abstract · 10 pages, 2 figures, 3 tables. Accepted at MLCN 2026, a workshop held in conjunction with MICCAI 2026; to appear in Springer LNCS

A capable brain-MRI report generator can still be, in effect, diagnostically silent. When a multi-chain chain-of-thought (CoT) reporter built on a medical Mistral-7B backbone is evaluated on held-out cohorts, it names most meningiomas and almost all metastases "glioma" (diagnosis recall 0.44/0.07). Yet the answer is not absent from the model: a supervised linear probe applied to its frozen segmentation features recovers the three tumour cohorts at 0.82 macro-F$_1$ (5-fold cross-validation; chance $\approx$0.33). We introduce NeuroFusion, an assistive reporter that surfaces this latent signal rather than overriding it: discriminative field-classifier heads over per-lesion features condition a fast, single-pass draft-then-review decoder on their committed outputs. Built on the identical Mistral backbone, this restores the diagnosis (meningioma 0.92, metastasis 0.75) and wins 8 of 9 prose-content comparisons across three held-out cohorts (RaTEScore, RadGraph-F$_1$, GREEN; Holm-corrected paired BCa), with no significant loss on the ninth, at 5-6x lower latency ($\approx$80 vs. 457 s/case). A controlled negative result sharpens the mechanism: a learned diagnosis pin that overrides the decoder instead of merely informing it collapses out-of-distribution metastasis recall to 0.03. Grammar-constrained decoding keeps 92.3% of records schema-valid, making every sentence entailment-checkable (7.5% contradicted vs. 36.8% for the direct baseline). In a blinded nine-case pilot, two board-certified neurologists independently rated NeuroFusion highest in every tumour type, the only system with zero critical errors, and gave it the top-rated sign-off in eight of nine cases (six outright, two ties).

0.46

CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

cs.CV ·2026-08-18 ·Alexandre G. Leclercq, Noémie N. Moreau, Hugo Audebert, Andros Nassar, Thomas Cochin +19 more
top venue similarity 0.59
Abstract · 9 pages, 2 figures,

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction, disease progression modelling, and personalized medicine. We present CFB-GBM v2.0, an extension of our previously released CFB-GBM dataset comprising 264 GBM patients treated according to the standard Stupp protocol. The primary contribution of this release is the completion of Gross Tumour Volume (GTV) delineations across all available timepoints ($t_0$, $t_1$ and $t_2$), increasing the overall GTV completion rate from 35% to 97%. This was achieved using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on CFB-GBM ground-truth contours, with the generated segmentations validated by five radiation oncologists. From these longitudinal GTV annotations, volumetric RANO 2.0 response category labels were derived for all available temporality pairs ($t_0 \rightarrow t_1$, $t_0 \rightarrow t_2$ and $t_1 \rightarrow t_2$). To further ease dataset usability and reproducibility, brain masks computed with HD-BET and pre-computed radiomic features extracted with PyRadiomics are provided for each patient timepoint and MRI modality. Additionally, the WHO classification guideline (2016 vs. 2021) applicable to each patient's diagnosis is now explicitly documented. CFB-GBM v2.0 is publicly available on The Cancer Imaging Archive (TCIA) at https://www.cancerimagingarchive.net/collection/cfb-gbm .

0.67

A Tumour-Aware Multimodal Framework for Explainable Prediction of IDH Mutation in Gliomas from Multi-Sequence MRI

eess.IV cs.CV ·2026-11-13 ·Tahsien Al-Quraishi, Waseem Alwan Zaboon, O. S. Albahri, Raza Nowrozy
similarity 0.59
Abstract · 45 pages, 12 figures, 4 tables. Preprint of an article submitted for consideration in International Journal of Information Technology & Deci…

Accurate prediction of isocitrate dehydrogenase (IDH) mutation status is essential for glioma diagnosis, prognosis, and treatment planning. Although recent deep learning approaches have demonstrated promising performance, many rely on whole-brain feature extraction and provide limited interpretability. This study proposes a tumour-aware multimodal framework for explainable, non-invasive prediction of IDH mutation status from multiparametric magnetic resonance imaging (MRI). The proposed framework integrates four MRI sequences (T1, T1CE, T2, and FLAIR), tumour subregion segmentation, quantitative radiomic descriptors, and clinical information within a unified deep learning architecture. An ablation study was conducted to evaluate the contribution of tumour-aware learning, radiomic features, and clinical variables. Model performance was assessed using multiple complementary evaluation metrics, including accuracy, precision, recall, F1-score, balanced accuracy, receiver operating characteristic analysis, confusion matrix evaluation, and Grad-CAM visualisation. Experimental results demonstrated that the proposed multimodal framework consistently outperformed the baseline MRI-only model, with the Clinical Fusion model achieving the strongest overall predictive performance. The integration of tumour-aware learning, radiomic descriptors, and clinical information progressively improved classification performance, while Grad-CAM visualisations indicated that the model predominantly focused on biologically relevant tumour regions. These findings suggest that tumour-aware multimodal feature integration enables accurate, interpretable, and non-invasive molecular profiling of gliomas and provides a promising foundation for future clinical decision support in precision neuro-oncology.

0.12